Pay in 4 interest-free payments of $5.28 Learn more
Ships within 48 hours · Estimated delivery Oct 11 - Oct 16
To qualify you must be: Healthy Male or Female Aged 30-55 inclusive at screening BMI 18-32 at screening A non-smoker This study will include 1 inpatient stay of 7 days/6 nights, and 1 inpatient stay of up to 12 days/11 nights, with 1 follow-up visit 14 days after discharge Qualified participants will be compensated up to $8,300 for their study-related time and travel
M., Citi, S
Rosenberg G, Angel I, Kozak A
If CagriSema receives regulatory approval, it would likely become the standard of care for obesity treatment, potentially displacing semaglutide and tirzepatide as first-line options
Gene 533, 469476 (2014)
US$ 27.02
US$ 29.41
US$ 22.45
US$ 21.87
